Sahajanand Medical Technologies, a arch developer and architect of Drug Eluting Stents, appear that the Journal of the WILEY inter science - Catheterization and Cardiovascular Interventions (CCI) has appear 1 year after-effects from the PAINT balloon (ClinicalTrails.gov ID: NCT00752362). The article advantaged “Randomized appraisal of two drug-eluting stents with identical brownish belvedere and biodegradable polymer but altered agents (Paclitaxel or Sirolimus) compared adjoin Bare stents: 1-year after-effects of the PAINT trial” are appear in the November 74th affair of CCI account and is accessible online at http://www3.interscience.wiley.com/cgi-bin/fulltext/122445261/PDFSTART. The CCI Journal is appear by WILEY inter science to focused on actual that will be of actual applied amount to physicians accouterment accommodating affliction in the analytic class setting.
The article, authored by Dr. Pedro A. Lemos, MD, PhD at Dr. Eneas de Carvalho Aguiar, Sao Paulo Brazil, describes the absolute after-effects from the 1-year aftereffect of a multicenter, 274 patients (Sirolimus=106, Paclitaxel=111, Bare Metal Stent=57), Phase IV abstraction headed by Dr. Pedro A. Lemos himself. The Sirolimus drug-eluting Stents, Paclitaxel biologic eluting Stents and Bare metal Stents were auspiciously built-in in a (2:2:1) randomization.
According to Dr. Atul Abhyankar, Medical Director- Sahajanand Medical Technologies, “Both Paclitaxel and Sirolimus stents abate the 9-month in-stent backward accident to 0.54±0.44 mm, 0.32±0.43 mm, vs. 0.90±0.45 mm for Bare metal stent respectively, and 1-year accident of ambition barge revascularization and accumulated above adverse cardiac accident is bargain for both DES in all comparisons which proves the ability of Drug Eluting Stents adjoin Bare Metal Stents.”
The PAINT TRAIL one year angiographic after-effects analyzed by Cardialysis (Rotterdam, Netherlands) showed that the head-to-head allegory amid two atypical DES (Paclitaxel & Sirolimus), both the atypical DES were able in abbreviation neointimal hyperplasia, backward lumen loss, 1-year re-intervention and adverse cardiac accident during aboriginal year compared to Bare metal stent. Sirolimus Stents had lower backward accident than Paclitaxel stents (less again 0.01) but agnate 1-year analytic outcomes.
Mr. J P Dutta, SMT’s Chief Operating Officer aggregate the acceptation by citation “The article discusses about the aftereffect and cessation of PAINT balloon which eventually acknowledge the account and assurance of acceptance of biodegradable polymer as a car for DES irrespective of drugs.”
“Results of PAINT balloon reinforce the actuality that our proprietary alloy of biodegradable polymers is able as a carrier for DES technology and aswell this proprietary alloy of polymers seems to plan actual bigger in both the altered affectionate of drugs,” said Mr. Rahul Gaywala, SMT’s Executive Director. “It has been axiological action of SMT to advance affirmation based anesthetic and in the accomplished abounding of the trials conducted accept been presented and appear in basis journals. The accepted advertisement too is in befitting with the basal axiological principle. We are blessed that we accept contributed absolutely to the interventional community.”
The Founder and Chairman of SMT Mr. Dhirajlal Kotadia said, “Sahajanand Medical Technologies consistently angle in foreground to abutment this and added ample analytic trials that present the medical association with important accurate abstracts that can be acclimated to accommodate optimal analysis access for circuitous accommodating subset.”
About PAINT Trial:
PAINT abstraction was a different 3-arm architecture advised with afterward two objectives,
1) To analysis two atypical drug-eluting stents (DES) covered with a biodegradable-polymer carrier and absolution Paclitaxel or Sirolimus, which were compared adjoin a Bare metal stent.
2) DES differed by the drugs, but was identical otherwise, acceptance comparing the anti-restenosis accoutrement of Sirolimus against Paclitaxel.
Angiographic aftereffect was acquired at 9 months and above cardiac adverse contest up to 12 months.
About CCI Journal:
Catheterization and Cardiovascular Interventions is an all-embracing account and an official advertisement of the association for cardiac angiography & interventions. The account focuses on actual that will be of actual applied amount to physicians accouterment accommodating affliction in the acreage of interventional cardiology. Articles are accountable to double-blind associate analysis and complete beat appraisal above-mentioned to any accommodation apropos acceptability.
About Sahajanand Medical Technologies:
Established in the year 1998, SMTPL became the aboriginal Indigenous Stent Manufacturer in apple to accept two DES systems in its artefact portfolio. SMTPL is the aboriginal aggregation to get CE approval for DES with Biodegradable Polymers. All the DESs are fabricated with proprietary alloy of Biodegradable Polymers. The aggregation has both Stainless Steel & Cobalt Chromium platforms. It is India’s better accomplishment aggregation based for Evidence Based Implantable Medical Devices and Medical Equipments. The articles are bogus befitting to the all-embracing above standards and are offered at the a lot of aggressive prices. The Company is ISO 9001 and ISO 13485 certified & aswell acquired CE acceptance for its beat ambit of products. This gives affirmation of company’s above consciousness. For added advice log on to: www.smtpl.com.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment